香港联交所最新资料显示，1月5日，Norges Bank减持康龙化成（300759）(03759)365.95万股，每股作 价20.6572港元，总金额约为7559.50万港元。减持后最新持股数目约为1454.57万股，最新持股比例为 4.94%。 ...

智通财经APP获悉，香港联交所最新资料显示，1月5日，Norges Bank减持康龙化成(03759)365.95万股， 每股作价20.6572港元，总金额约为7559.50万港元。减持后最新持股数目约为1454.57万股，最新持股比 例为4.94%。 ...

Group 1 - The CRO (Contract Research Organization) sector in the Hong Kong stock market has shown strong performance, with notable gains across various companies [1] - Specifically, Kailaiying has increased by over 7%, while Tigermed and Zhaoyan Pharmaceutical have risen by over 5% [1] - Other companies such as WuXi AppTec and Kanglong Chemical have seen increases of over 3%, and WuXi Biologics and Kingsoft have gained over 2% [1]

Core Viewpoint - The CRO and CDMO sectors are experiencing a collective rise in stock prices, driven by a combination of recovering demand and supply-side improvements, with expectations for profitability and valuation to increase simultaneously, referred to as a "Davis Double Play" [1][2] Group 1: Stock Performance - Key stocks in the CRO sector have seen significant gains, with Kelaiying up 6.27% to HKD 82.2, Tigermed up 5.48% to HKD 48.92, and Zhaoyan New Drug up 5.19% to HKD 23.52 [1] - Other notable increases include Kanglong Chemical up 3.37% to HKD 22.68 and WuXi AppTec up 3.12% to HKD 109.1 [1] Group 2: Industry Outlook - According to Zhongtai Securities, the CRO and CDMO industries are expected to benefit from a combination of external and internal demand recovery, with supply gradually clearing [1] - The anticipated easing of monetary policy in late 2024 and subsequent geopolitical negotiations in 2025 are expected to improve market sentiment and drive demand recovery [1] - The industry is projected to see significant policy support and the realization of large-scale domestic innovative drug business development starting in 2025 [1] Group 3: Order Growth and Market Dynamics - Industrial insights from Xingye Securities indicate that many CROs are experiencing accelerated order signing, with project volumes achieving double-digit growth [2] - There is a noted upward trend in pricing for experimental monkeys, safety evaluation quotes, and clinical project costs since Q4, reflecting strong customer demand [2] - The global positioning of Chinese CDMOs in the supply chain remains irreplaceable, and the anticipated Federal Reserve interest rate cuts are expected to boost early-stage global R&D demand [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | ...

公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2026年1月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 2. 股份分類 | 普通股 | 股份類別 | A | | 於香港聯交所上市 (註1) | | 否 | | | --- | --- | --- | --- | ...

转自：前瞻产业研究院 以下数据及分析来自于前瞻产业研究院医药研发外包(CRO)研究小组发布的《中国医药研发外包（CRO） 行业市场前瞻与投资战略规划分析报告》。 行业主要上市公司：目前国内CRO行业主要的上市公司有药明康德(603259.SH)、康龙化成(300759.SZ)、泰 格医药(300347.SZ)、凯莱英(002821.SZ)、昭衍新药(603127.SH)、九洲药业(603456.SH)、皓元医药 (688131.SH)、博腾股份(300363.SZ)、成都先导(688222.SH)、药石科技(300725.SZ)等。 本文核心数据：企业主营业务收入、企业经营毛利率 1、中国CRO产业链全景梳理 中国CRO产业链贯穿研发阶段、生产阶段和产品销售整个药品生命周期，分别对应药物研发服务(CRO)、 医药生产服务(CMO/CDMO)以及医药销售服务(CSO)。研发阶段覆盖临床前与临床两大核心环节，其中临 床前主要做有关药物发现、化合物合成、合成工艺研发及制剂研发等早期基础研发工作;临床阶段主要进行 临床试验、医学统计、数据整理与数据分析等流程。生产阶段，针对不同药物类型提供生产服务，化学原 料药包含了 ...

Group 1 - The medical ETF (512170) opened high on January 6, rising over 1% and reaching a 20-day high, with real-time transaction volume exceeding 350 million yuan. The ETF recorded a daily increase of over 5%, marking five consecutive days of gains [1][5] - Brain-computer interface stocks, including Sanbo Brain Science and Meihua Medical, both hit the 20% daily limit up, achieving two consecutive boards. Conversely, the CXO sector saw a pullback, with Tigermed falling over 1% [1][5] Group 2 - On January 5, 2026, Elon Musk announced that Neuralink plans to start large-scale production of brain-computer interface devices, advancing the commercialization of the technology. Concurrently, the National Medical Products Administration held a meeting to expedite the review and approval of related medical devices [3][6] - According to CITIC Securities, China's brain-computer interface technology is relatively advanced globally, with potential to cultivate leading companies in the sector. This could enhance the valuations of related listed companies in the secondary market and stimulate financing in the primary market, creating a synergy between capital and industry development [7] - Zhongtai Securities noted that the pharmaceutical sector is expected to rebound in 2025 after four consecutive years of decline, driven by the realization of innovative drug export logic and industry recovery post-policy reform. Certain areas of the medical device sector may also see a reversal of difficulties [7]

Group 1 - JPMorgan increased its stake in Kanglong Chemical (03759) by 1,456,225 shares at a price of HKD 19.388 per share, totaling approximately HKD 28.2333 million [2][4] - After the increase, JPMorgan's total shareholding in Kanglong Chemical reached approximately 15,810,300 shares, representing a stake of 5.24% [2][4]

智通财经APP获悉，香港联交所最新资料显示，12月30日，小摩增持康龙化成(03759)145.6225万股，每 股作价19.388港元，总金额约为2823.33万港元。增持后最新持股数目约为1581.03万股，最新持股比例 为5.24%。 ...